GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success
On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.
Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.
In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.
Shares closed up 1.5 percent to $66.19 in Tuesday's trading.
Latest Ratings for GWPH
|Mar 2016||Roth Capital||Maintains||Buy|
|Mar 2016||Numis Securities||Initiates Coverage on||Sell|
|Nov 2015||Roth Capital||Assumes||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.